Kopran Ltd expects impact on Q1FY22 results due to upgradation of Mahad facility

Kopran Research Laboratories Ltd., a wholly owned subsidiary has undertaken expansion and upgradation of various Plants at its Active Pharmaceutical Ingredients facility at Mahad since March 2021.

Due to the onset of the second wave of the Pandemic, the expansion work was delayed, especially because of non-availability of Workers and Industrial Oxygen. The expansions of two Plants were completed by April 2021 end and resumed operations. The expansion and upgradation of the Sterile Plant was completed and operations resumed by June 2021 end.

Due to the above, there would be an impact on the results of Quarter 1 of FY 2021-22.

Shares of KOPRAN LTD. was last trading in BSE at Rs.233 as compared to the previous close of Rs. 237.35. The total number of shares traded during the day was 58126 in over 1055 trades.

The stock hit an intraday high of Rs. 235.5 and intraday low of 225.5. The net turnover during the day was Rs. 13193163.

Source : Equity Bulls

Keywords